Reference

Comparative effects of chronic administration of the nonsteroidal antiandrogens flutamide and casodex on the reproductive system of the adult male rat

Comparative effects of chronic administration of the nonsteroidal antiandrogens flutamide and casodex on the reproductive system of the adult male rat. Chandolia, Ramesh K.; Weinbauer, Gerhard F.; Simoni, Manuela; Behre, Hermann M.; Nieschlag, Eberhard (Inst. Reprod. Med., Univ. Muenster, Muenster, Germany). Acta Endocrinol., 125(5), 547-55 (English) 1991. 13311-84-7 and 90357-06-5 are cas registry numbers of chemicals which are used as reagents here. CODEN: ACENA7. ISSN: 0001-5598. DOCUMENT TYPE: Journal CA Section: 1 (Pharmacology) The present studies were undertaken to compare the effects of long-term administration (3 and 8 wk) of casodex and flutamide on the pituitary-testicular axis, reproductive organ wts. and spermatogenesis in adult rats. Treatment with a gonadotropin-releasing hormone antagonist, known to suppress endogenous androgen prodn., served to compare the effects of removal of androgen with that of blocking androgen action. .

Oncologic, endocrine & metabolic Bicalutamide (Casodex)

Oncologic, endocrine & metabolic Bicalutamide (Casodex). Schellhammer, Paul (Eastern Virginia Med. Sch., Norfolk, VA 23507-1999, USA). Expert Opinion on Investigational Drugs, 5(12), 1707-1722 (English) 1996 Ashley Publications. CODEN: EOIDER. ISSN: 0967-8298. DOCUMENT TYPE: Journal; General Review CA Section: 1 (Pharmacology) Section cross-reference(s): 2 A review with 42 refs. Bicalutamide (Casodex) is a relatively new nonsteroidal antiandrogen indicated for use in combination therapy with castration for the treatment of advanced prostate cancer. Developed from a series of nonsteroidal compds. related to flutamide, bicalutamide is a potent, orally active, well tolerated anti-androgen with a half-life compatible with once-daily administration. In the clin. program in prostatic cancer, patients were exposed to bicalutamide in doses ranging from 10-600 mg. Doses of 10-200 mg have been shown to have intrinsic activity in terms of producing subjective improvement and objective responses, and daily doses of up to 600 mg are currently being evaluated. 90357-06-5 which is the cas registry number of some chemical is mentioned. Results of monotherapy studies reveal that 50 mg of bicalutamide is less effective than castration in patients with advanced disease; Phase III monotherapy studies are ongoing to compare 150 mg of bicalutamide with castration. In monotherapy studies, both 50 mg and 150 mg of bicalutamide have an advantage over castration in allowing patients to maintain libido and sexual potency. As combination therapy, 50 mg bicalutamide and a LH-releasing hormone (LHRH) analog is at least as effective as 750 mg of flutamide and LHRH analog and is better tolerated. The overall safety and tolerability profile of bicalutamide is indicative of a well tolerated therapy that has a relatively low incidence of treatment-related withdrawals. Because of its efficacy in combination with medical castration, its excellent safety profile, and its convenient once-daily oral formulation, bicalutamide represents a valid choice of anti-androgen therapy when used in combination with castration for patients with advanced prostate cancer. .